Optimal care for children and adolescents with type 1 diabetes is well described in guidelines, such as those of the International Society for Pediatric and Adolescent Diabetes. High-income countries can usually provide this, but the cost of this care is generally prohibitive for lowerincome countries. Indeed, in most of these countries, very little care is provided by government health systems, resulting in high mortality, and high complications rates in those who do survive.
| INTRODUCTION
Type 1 diabetes (T1D) occurs in children and adolescents across the world, and there are accepted international guidelines for effective management, notably from the International Society for Pediatric and Adolescent Diabetes (ISPAD). 1 In most well-resourced countries, the resources to achieve such care are essentially fully covered by the respective national health systems, 2 although there is a large variation in hemoglobin A1c (HbA1c) results between high-income western countries. 3 Furthermore, care is improving with advances in insulins, insulin pumps, glucose monitoring, and "closed-loop" systems. However, this is not the case in many middle-income or low-income countries. Insulin, blood glucose tests strips, and other components of care are often unavailable or remain inaccessible, as they must be purchased out-of-pocket by families. 2, [4] [5] [6] [7] Access to physicians and nurses skilled in T1D management and diabetes education is also very frequently limited. 2, 4 These deficiencies in T1D care have profound impacts. Mortality rates are very high in children and adolescents, 5, [8] [9] [10] [11] and for those who do survive, blood glucose control is poor and early chronic diabetes complications are frequent. [11] [12] [13] [14] [15] [16] These stark differences in outcomes compared to well-resourced countries are tragic for patients and families and deeply distressing for health professionals. While it is imperative that all countries aim for universal availability of comprehensive guidelines-based care, it is currently unrealistic to expect governments in less-resourced countries to provide all the components of comprehensive care recommended by the ISPAD guidelines. 1 Health budgets are limited and there are many competing demands, such as maternal and child health, infectious diseases, and other chronic health conditions.
To help facilitate the work of policy makers, health planners, professional and lay advocates, and the care providers in countries where comprehensive guidelines-based care is mostly inaccessible for young people with T1D, we have developed a "Levels of Care" framework for T1D care (Figure 1 ). There are three tiers of care: "minimal care"
(Levels 1A-1D), intermediate care" (Levels 2A-2B), and "comprehensive care (ISPAD guidelines)" (Levels 3A-3D). The tiers concept is based on the "minimal," "standard," and "Comprehensive" Care tiers in the International Diabetes Federation (IDF)'s "Global Guidelines for Type 2 Diabetes" published in 2005. 17 We replaced "Standard" with "Intermediate" as it more accurately describes a tier that represents an important step towards eventual provision of comprehensive care.
For each level, details on insulin therapy, blood glucose monitoring, HbA1c testing, complications screening, and diabetes education and multi-disciplinary team care are provided, as well as the expected intra-clinic range of mean clinic HbA1c and mortality and complications.
1.1 | Levels of care
1.1.1 | Tier 1: minimal care
"Minimal care" is defined by that which has been observed and reported in many less-resourced countries. 2, 5, 12, [18] [19] [20] [21] In the lowest level, designated 1A, human insulin (if available), is given through two injections daily. In many countries, only pre-mixed insulin is used as this is the only insulin provided in the public health system. 2, 12, 15, 22 Health facilities frequently lack any capacity to measure blood glucose. 5 This level of care has devastating outcomes. There is a high early mortality from ketoacidosis at onset, because of misdiagnosis or late diagnosis, and later from hypoglycemia and ketoacidosis. 2, 5, [8] [9] [10] [11] 21 There are also high rates of early complications, 12,14 with devastating long-term complications in some. 7, 25 HbA1c levels are high in Tanzania, means of 14% (130 mmol/mol), 14 12.6% (114 mmol/mol), 12 and 12.3% (111 mmol/mol) 19 have been reported, and in India 13.0%
(119 mmol/mol) has been documented. 26 The next steps in care (Levels 1B and 1C) are the introduction of SMBG at a frequency of two to three tests per week to two tests per day (depending on resources), and human short-and long-acting insulin are given through two injections per day. Education regarding FIGURE 1 Levels of type 1 diabetes care in children and adolescents insulin dosage adjustment is critical in optimizing use of these insulins. 4 in Sudan (note that two of these studies 4, 27 are older papers from the mid 1990). Results will vary according to the particular country situation, whether improved care such as SMBG is available to all or some, and also the age distribution of the clinic population, as HbA1c tends to be higher in adolescents than in pre-pubertal children or adults. some patients were on human insulin and some on analogs. Interestingly, these levels are even similar to those seen in some high-income countries with substantially more resources. 3, 29, 43 Optimally in this tier, glucagon would also be available; however, it is rarely provided by government health services in less-resourced countries, 2, 44 and the out-of-pocket cost, if it can be purchased at all in these countries, is unaffordable for many.
Mortality in this tier of care is substantially lower, with reported rates of 2.0 per 1000 patient years in Uzbekistan 25 and 2.2 per 1000 in Bolivia. 7 With HbA1c levels 8% to 9.5% (64-80 mmol/mol), longterm complications would also be expected to be much reduced. 31, 45 This care is outlined in the LFAC/ISPAD "Pocketbook Guideline for Management of Diabetes in Childhood and Adolescence in Underresourced Countries, 46 and in the Changing Diabetes in Children's program manual "Diabetes in Children and Adolescents". 47 Within individual countries, thought should be given so that staff at varying levels of the respective health system, (national hospital, provincial hospital, rural health centre, etc.) have the training and resources to provide emergency and chronic care and complications screening at the highest practical level. National treatment guidelines tailored to the specific country situation would aid this.
| Tier 3: comprehensive care (ISPAD guidelines)
It is beyond the scope of this paper to fully describe comprehensive, guidelines-based care. This is detailed in the ISPAD Clinical Practice Consensus Guidelines 2018. 1 Multidisciplinary care is provided by a team comprising a pediatric diabetologist, nurse educator, dietitian, social worker, and psychologist.
The insulin regimen is either basal bolus or, if possible, by continuous subcutaneous infusion with an insulin pump. 33 There is sufficient access to SMBG supplies to permit 4 to 6 or more tests per day, and in many situations, there is access to continuous glucose monitoring (CGM), which has added advantages in some contexts. 31 Most recently, "closed-loop" devices are becoming widely used that link the insulin pump to the CGM device. These advances are represented in Figure 1 by Levels 3A to 3D.
Full complications screening at the frequency stipulated by the guidelines should be conducted, including, in addition to those outlined in intermediate care, fundus examination by bio-microscopy or photography, and screening for thyroid and celiac disease. 45 Clinicbased, and if possible national, registries should be instituted as part of comprehensive care, with participation in benchmarking efforts such as SWEET 43 providing further benefits.
With such care as the norm, mortality is rare. 48 23 We also recommend that both mean and median data to be presented in papers to aid comparisons, that HbA1c levels are presented in both IFCC (mmol/mol) and DCCT/NGSP levels (%), and that blood glucose is presented as both mmol/L and mg/dL.
In conclusion, we hope this stratified set of levels of care will help not only in the standard description of care across the world, but also provide a framework that will enable health providers and planners to set treatment goals and fund and implement plans to meet those goals.
